SAGE Therapeutics (SAGE) Misses Q2 EPS by 22c
Tweet
Share
E-mailGet Alerts SAGE Hot Sheet
Join SI Premium – FREE
SAGE Therapeutics (NASDAQ: SAGE) reported Q2 EPS of ($0.90), $0.22 worse than the analyst estimate of ($0.68).
For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Super Micro Computer rises on AI server market optimism
- RBC Capital Starts Tabcorp Holdings (TAH:AU) (TABCF) at Outperform
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
